Free Trial
NASDAQ:CRBP

Corbus Pharmaceuticals Q1 2025 Earnings Report

Corbus Pharmaceuticals logo
$7.48 -0.09 (-1.19%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals EPS Results

Actual EPS
-$1.39
Consensus EPS
-$1.26
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Corbus Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Corbus Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

Corbus Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Corbus Pharmaceuticals Earnings Headlines

B. Riley Has Negative Forecast for CRBP Q2 Earnings
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
Research Analysts Offer Predictions for CRBP Q2 Earnings
Wedbush Expects Reduced Earnings for Corbus Pharmaceuticals
See More Corbus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ:CRBP), a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

View Corbus Pharmaceuticals Profile

More Earnings Resources from MarketBeat